BC Week In Review | Dec 1, 2017
Clinical News

JnJ begins Phase IIb trial for mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill...
BC Extra | Dec 1, 2017
Clinical News

J&J begins Phase IIb trial of mosaic HIV vaccine

Johnson & Johnson (NYSE:JNJ) said it began the first trial designed to test the efficacy of a mosaic-based vaccine to prevent HIV infection. The Phase IIb trial -- Imbokodo -- is co-funded by the Bill...
Items per page:
1 - 2 of 2